Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CASSAVA SCIENCES, INC.

(SAVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
47.12(c) 41.79(c) 43.92(c) 43.95(c) 46.93 Last
5 662 976 7 942 263 6 623 981 4 409 292 3 381 913 Volume
-6.95% -11.31% +5.10% +0.07% +6.78% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -21,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -73,3x
Yield 2021 -
Sales 2022 66,7 M - -
Net income 2022 -32,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -120x
Yield 2022 -
Capitalization 1 759 M 1 759 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 26,4x
Nbr of Employees 11
Free-Float 93,5%
More Financials
Company
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimers disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the... 
More about the company
Ratings of Cassava Sciences, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D
More Ratings
All news about CASSAVA SCIENCES, INC.
09/16DEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming ..
PR
09/16CASSAVA SCIENCES : HAGENS BERMAN Encourages Cassava Sciences (SAVA) Investors wi..
PR
09/14GLANCY PRONGAY & MURRAY LLP : Reminds Investors of Looming Deadline in the Class..
PR
09/13SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..
PR
09/12SAVA SHAREHOLDER REMINDER : Kessler Topaz Meltzer & Check, LLP Reminds Sharehold..
PR
09/10SAVA SHAREHOLDER ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds Cassava Scie..
BU
09/10CASSAVA SCIENCES : to Present at H.C. Wainwright's 23rd Annual Global Investment..
AQ
09/09CASSAVA SCIENCES : to Present at H.C. Wainwright's 23rd Annual Global Investment..
AQ
09/07CASSAVA SCIENCES SHAREHOLDER ALERT B : Kahn Swick & Foti, LLC Reminds Investors ..
BU
09/07CASSAVA SCIENCES : Corporate Presentation – September 2021
PU
09/07CASSAVA SCIENCES : B. Riley Lowers Cassava Sciences' PT to $108 from $145 on Inv..
MT
09/06CASSAVA SCIENCES : ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Cassa..
PR
09/06CASSAVA SCIENCES : Releases a Public Statement Regarding Recent Allegations
AQ
09/05SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..
PR
09/04KESSLER TOPAZ MELTZER & CHECK, LLP : Securities Fraud Class Action Lawsuit Filed..
BU
More news
News in other languages on CASSAVA SCIENCES, INC.
09/03Les actions du secteur de la santé connaissent une reprise modeste et augment..
09/03Les actions du secteur de la santé cherchent toujours une direction
More news
Analyst Recommendations on CASSAVA SCIENCES, INC.
More recommendations
Chart CASSAVA SCIENCES, INC.
Duration : Period :
Cassava Sciences, Inc. Technical Analysis Chart | SAVA | US14817C1071 | MarketScreener
Technical analysis trends CASSAVA SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 43,95 $
Average target price 140,67 $
Spread / Average Target 220%
EPS Revisions
Managers and Directors
Remi Barbier Chairman, President & Chief Executive Officer
Eric J. Schoen Chief Financial Officer
Nadav Friedmann Director, Chief Operating & Medical Officer
James W. Kupiec Chief Clinical Development Officer
Michael Zamloot Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
CASSAVA SCIENCES, INC.544.43%1 759
BIONTECH SE357.13%90 003
GILEAD SCIENCES, INC.22.43%89 434
REGENERON PHARMACEUTICALS35.20%67 910
WUXI APPTEC CO., LTD.35.75%65 728
VERTEX PHARMACEUTICALS-20.83%48 539